Application of fullerenes in nanomedicine: An update

Nanomedicine

Volumn 8, Issue 7, 2013, Pages 1191-1208

  Dellinger, Anthony ^a   Zhou, Zhiguo ^b   Connor, James ^c   Madhankumar, Ab ^c   Pamujula, Sarala ^a   Sayes, Christie M ^a,d   Kepley, Christopher L ^a  

^a Joint School of Nanoscience and Nanoengineering   (United States)

^b LUNA INNOVATIONS INC   (United States)

^c PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^d RTI INTERNATIONAL   (United States)

Author keywords

arthritis; asthma; atherosclerosis; diagnostic; fullerene; glioblastoma; multiple sclerosis; theranostic; therapeutic

Indexed keywords

FULLERENE DERIVATIVE; GADOLINIUM;

ALLERGIC ENCEPHALOMYELITIS; ANTIBACTERIAL ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTIVIRAL ACTIVITY; ASTHMA; ATHEROSCLEROSIS; BRAIN CANCER; CANCER CELL DESTRUCTION; DIAGNOSTIC IMAGING; DRUG DELIVERY DEVICE; DRUG EFFICACY; DRUG POTENCY; EFFECTOR CELL; HUMAN; INFLAMMATORY DISEASE; MULTIPLE SCLEROSIS; NANOMEDICINE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS;

EID: 84879633959     PISSN: 17435889     EISSN: 17486963     Source Type: Journal    
DOI: 10.2217/nnm.13.99     Document Type: Review

References (105)

1. Rao CNR, Cheetham AK. Science and technology of nanomaterials: current status and future prospects. J. Mater. Chem. 11(12), 2887-2894 (2001).
2. Liu Z, Robinson JT, Tabakman SM, Yang K, Dai HJ. Carbon materials for drug delivery and cancer therapy. Mater. Today 14(7-8), 316-323 (2011).
3. Lu FS, Gu LR, Meziani MJ et al. Advances in bioapplications of carbon nanotubes. Adv. Mater. 21(2), 139-152 (2009).
4. Sun Z, Liu Z, Meng J et al. Carbon nanotubes enhance cytotoxicity mediated by human lymphocytes in vitro. PloS One 6(6), e21073 (2011).
5. Shen H, Zhang LM, Liu M, Zhang ZJ. Biomedical applications of graphene. Theranostics 2(3), 283-294 (2012).
6. Feng LZ, Zhang SA, Liu ZA. Graphene based gene transfection. Nanoscale 3(3), 1252-1257 (2011).
7. Basso AS, Frenkel D, Quintana FJ et al. Reversal of axonal loss and disability in a mouse model of progressive multiple sclerosis. J. Clin. Invest. 118(4), 1532-1543 (2008). (Pubitemid 351500446)
8. Dugan LL, Turetsky DM, Du C et al. Carboxyfullerenes as neuroprotective agents. Proc. Natl Acad. Sci. USA 94(17), 9434-9439 (1997). (Pubitemid 27357847)
9. Bosi S, Da RT, Spalluto G, Balzarini J, Prato M. Synthesis and anti-HIV properties of new water-soluble bis-functionalized[60]fullerene derivatives. Bioorg. Med. Chem. Lett. 13(24), 4437-4440 (2003). (Pubitemid 37490833)
10. Marchesan S, Da RT, Spalluto G, Balzarini J, Prato M. Anti-HIV properties of cationic fullerene derivatives. Bioorg. Med. Chem. Lett. 15(15), 3615-3618 (2005). (Pubitemid 40942069)
11. Berger CS, Marks JW, Bolskar RD, Rosenblum MG, Wilson LJ. Cell internalization studies of gadofullerene-(ZME-018) immunoconjugates into A375m melanoma cells. Transl. Oncol. 4(6), 350-354 (2011).
12. Daroczi B, Kari G, McAleer MF, Wolf JC, Rodeck U, Dicker AP. In vivo radioprotection by the fullerene nanoparticle DF-1 as assessed in a zebrafish model. Clin. Cancer Res. 12(23), 7086-7091 (2006). (Pubitemid 44974508)
13. Lai YL, Murugan P, Hwang KC. Fullerene derivative attenuates ischemia-reperfusion-induced lung injury. Life Sci. 72(11), 1271-1278 (2003). (Pubitemid 36044680)
14. Gonzalez KA, Wilson LJ, Wu W, Nancollas GH. Synthesis and in vitro characterization of a tissue-selective fullerene: vectoring C(60)(OH)(16)AMBP to mineralized bone. Bioorg. Med. Chem. 10(6), 1991-1997 (2002). (Pubitemid 34286393)
15. Dellinger A, Zhou Z, Lenk R, Macfarland D, Kepley CL. Fullerene nanomaterials inhibit phorbol myristate acetate-induced inflammation. Exp. Dermatol. 18(12), 1079-1081 (2009).
16. Tsao N, Luh TY, Chou CK et al. In vitro action of carboxyfullerene. J. Antimicrob. Chemother. 49(4), 641-649 (2002). (Pubitemid 34428979)
17. Quick KL, Ali SS, Arch R, Xiong C, Wozniak D, Dugan LL. A carboxyfullerene SOD mimetic improves cognition and extends the lifespan of mice. Neurobiol. Aging 29(1), 117-128 (2008). (Pubitemid 350102712)
18. Baati T, Bourasset F, Gharbi N et al. The prolongation of the lifespan of rats by repeated oral administration of [60]fullerene. Biomaterials 33(19), 4936-4946 (2012).
19. Yamago S, Tokuyama H, Nakamura E et al. In vivo biological behavior of a water-miscible fullerene: 14C labeling, absorption, distribution, excretion and acute toxicity. Chem. Biol. 2(6), 385-389 (1995).
20. Ryan JJ, Bateman HR, Stover A et al. Fullerene nanomaterials inhibit the allergic response. J. Immunol. 179(1), 665-672 (2007). (Pubitemid 46986585)
21. Dellinger A, Zhou Z, Norton SK, Lenk R, Conrad D, Kepley CL. Uptake and distribution of fullerenes in human mast cells. Nanomedicine 6(4), 575-582 (2010).
22. Norton SK, Dellinger A, Zhou Z et al. A new class of human mast cell and peripheral blood basophil stabilizers that differentially control allergic mediator release. Clin. Transl. Sci. 3(4), 158-169 (2010).
23. Galli SJ, Tsai M, Piliponsky AM. The development of allergic inflammation. Nature 454(7203), 445-454 (2008).
24. Kobayashi T, Miura T, Haba T et al. An essential role of mast cells in the development of airway hyperresponsiveness in a murine asthma model. J. Immunol. 164(7), 3855-3861 (2000). (Pubitemid 30169844)
25. Williams CM, Galli SJ. Mast cells can amplify airway reactivity and features of chronic inflammation in an asthma model in mice. J. Exp. Med. 192(3), 455-462 (2000). (Pubitemid 30629171)
26. Gordon JR, Galli SJ. Mast cells as a source of both preformed and immunologically inducible TNF-alpha/cachectin. Nature 346, 274-276,1990
27. Brightling C, Berry M, Amrani Y. Targeting TNF-alpha: a novel therapeutic approach for asthma. J. Allergy Clin. Immunol. 121(1), 5-10 (2008).
28. Kepley CL, Mcfeeley PJ, Oliver JM, Lipscomb MF. Immunohistochemical detection of human basophils in postmortem cases of fatal asthma. Am. J. Respir. Crit. Care Med. 164(6), 1053-1058 (2001). (Pubitemid 32971658)
29. Kepley CL, Craig SS, Schwartz LB. Identification and partial characterization of a unique marker for human basophils. J. Immunol. 154(12), 6548-6555 (1995).
30. Schroeder JT. Basophils beyond effector cells of allergic inflammation. Adv. Immunol. 101, 123-161 (20090
31. Jackson DJ, Sykes A, Mallia P, Johnston SL. Asthma exacerbations: origin, effect, and prevention. J. Allergy Clin. Immunol. 128(6), 1165-1174 (2011).
32. Norton SK, Wijesinghe DS, Dellinger A et al. Epoxyeicosatrienoic acids are involved in the C(70) fullerene derivative-induced control of allergic asthma. J. Allergy Clin. Immunol. 130(3), 761-769 (2012).
33. Sudhahar V, Shaw S, Imig JD. Epoxyeicosatrienoic acid analogs and vascular function. Curr. Med. Chem. 17(12), 1181-1190 (2010).
34. Pfister SL, Gauthier KM, Campbell WB. Vascular pharmacology of epoxyeicosatrienoic acids. Adv. Pharmacol. 60, 27-59 (2010).
35. Morin C, Rousseau E. Effects of 5-oxo-ETE and 14,15-EET on reactivity and Ca2+ sensitivity in guinea pig bronchi. Prostaglandins Other Lipid Mediat. 82(1-4), 30-41 (2007). (Pubitemid 44880170)
36. Morin C, Sirois M, Echave V, Gomes MM, Rousseau E. EET displays anti-inflammatory effects in TNF-alpha stimulated human bronchi: putative role of CPI-17. Am. J. Respir. Cell Mol. Biol. 38(2), 192-201 (2008). (Pubitemid 351162841)
37. Node K, Huo Y, Ruan X et al. Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. Science 285(5431), 1276-1279 (1999). (Pubitemid 29398616)
38. Nigrovic PA, Lee DM. Synovial mast cells: role in acute and chronic arthritis. Immunol. Rev. 217, 19-37 (2007) (Pubitemid 46718141)
39. Woolley DE. The mast cell in inflammatory arthritis. N. Engl. J. Med. 348(17), 1709-1711 (2003). (Pubitemid 36459479)
40. Irani AA, Golzar N, Deblois G, Gruber B, Schwartz LB. Distribution of mast cell subsets in rheumatoid arthritis and osteoarthritis synovia. Arthritis Rheum. 30, 66 (1987).
41. Bridges AJ, Malone DG, Jicinsky J et al. Human synovial mast cell involvement in rheumatoid arthritis and osteoarthritis: relationship to disease type, clinical activity, and antirheumatic therapy. Arthritis Rheum. 34, 1116-1124 (1991).
42. Gotis-Graham I, Smith MD, Parker A, Mcneil HP. Synovial mast cell responses during clinical improvement in early rheumatoid arthritis. Ann. Rheum. Dis. 57(11), 664-671 (1998). (Pubitemid 28558970)
43. Lavery JP, Lisse JR. Preliminary study of the tryptase levels in the synovial fluid of patients with inflammatory arthritis. Ann. Allergy 72, 425-427 (1994). (Pubitemid 24148007)
44. Lee DM, Friend DS, Gurish MF, Benoist C, Mathis D, Brenner MB. Mast cells: a cellular link between autoantibodies and inflammatory arthritis. Science. 297(5587), 1689-1692 (2002). (Pubitemid 35000781)
45. Dinser R. Animal models for arthritis. Best Pract. Res. Clin. Rheumatol. 22(2), 253-267 (2008). (Pubitemid 351606944)
46. Nigrovic PA, Lee DM. Mast cells in autoantibody responses and arthritis. Novartis Found. Symp. 271, 200-209 (2005).
47. Winyard PG, Ryan B, Eggleton P et al. Measurement and meaning of markers of reactive species of oxygen, nitrogen and sulfur in healthy human subjects and patients with inflammatory joint disease. Biochem. Soc. Trans. 39, 1226-1232 (2011).
48. Zhou Z, Lenk RP, Dellinger A, Wilson SR, Sadler R, Kepley CL. Liposomal formulation of amphiphilic fullerene antioxidants. Bioconjug. Chem. 21(9), 1656-1661 (2010).
49. Ehrich M, van Tassell R, Li Y, Zhou Z, Kepley CL. Fullerene antioxidants decrease organophosphate-induced acetylcholinesterase inhibition in vitro. Toxicol. In Vitro 25(1), 301-307 (2011).
50. Zhao W, Gomez G, Macey M, Kepley CL, Schwartz LB. In vitro desensitization of human skin mast cells. J. Clin. Immunol. 32(1), 150-160 (2011).
51. Chirico F, Fumelli C, Marconi A et al. Carboxyfullerenes localize within mitochondria and prevent the UVB-induced intrinsic apoptotic pathway. Exp. Dermatol. 16(5), 429-436 (2007). (Pubitemid 46585371)
52. Fumelli C, Marconi A, Salvioli S et al. Carboxyfullerenes protect human keratinocytes from ultraviolet-B-induced apoptosis. J. Invest. Dermatol. 115(5), 835-841 (2000).
53. Pitman N, Asquith DL, Murphy G, Liew FY, Mcinnes IB. Collagen-induced arthritis is not impaired in mast cell-deficient mice. Ann. Rheum. Dis. 70(6), 1170-1171 (2011).
54. Brown MA, Tanzola MB, Robbie-Ryan M. Mechanisms underlying mast cell influence on EAE disease course. Mol. Immunol. 38(16-18), 1373-1378 (2002). (Pubitemid 35253780)
55. Gregory GD, Bickford A, Robbie-Ryan M, Tanzola M, Brown MA. MASTering the immune response: mast cells in autoimmunity. Novartis Found. Symp. 271, 215-225; discussion 225-231 (2005).
56. Secor VH, Secor WE, Gutekunst CA, Brown MA. Mast cells are essential for early onset and severe disease in a murine model of multiple sclerosis. J. Exp. Med. 191(5), 813-822 (2000).
57. Li LB, Reith ME. Modeling of the interaction of Na+ and K+ with the binding of dopamine and [3H]WIN 35,428 to the human dopamine transporter. J. Neurochem. 72(3), 1095-1109 (1999). (Pubitemid 29085024)
58. Dugan LL, Gabrielsen JK, Yu SP, Lin TS, Choi DW. Buckminsterfullerenol free radical scavengers reduce excitotoxic and apoptotic death of cultured cortical neurons. Neurobiol. Dis. 3(2), 129-135 (1996). (Pubitemid 26275342)
59. Ali SS, Hardt JI, Quick KL et al. A biologically effective fullerene (C60) derivative with superoxide dismutase mimetic properties. Free Radic. Biol. Med. 37(8), 1191-1202 (2004). (Pubitemid 39296744)
60. Borland MK, Trimmer PA, Rubinstein JD et al. Chronic, low-dose rotenone reproduces Lewy neurites found in early stages of Parkinson's disease, reduces mitochondrial movement and slowly kills differentiated SH-SY5Y neural cells. Mol. Neurodegener. 3, 21 (2008).
61. Gilgun-Sherki Y, Melamed E, Offen D. The role of oxidative stress in the pathogenesis of multiple sclerosis: the need for effective antioxidant therapy. J. Neurol. 251(3), 261-268 (2004). (Pubitemid 38387142)
62. Bakry R, Vallant RM, Najam-Ul-Haq M et al. Medicinal applications of fullerenes. Int. J. Nanomedicine 2(4), 639-649 (2007).
63. Mody VV, Nounou MI, Bikram M. Novel nanomedicine-based MRI contrast agents for gynecological malignancies. Adv. Drug Deliv. Rev. 61(10), 795-807 (2009).
64. Nitta N, Seko A, Sonoda A et al. Is the use of fullerene in photodynamic therapy effective for atherosclerosis? Cardiovasc. Intervent. Radiol. 31(2), 359-366 (2008). (Pubitemid 351421911)
65. Bolskar RD. Gadofullerene MRI contrast agents. Nanomedicine (Lond.) 3(2), 201-213 (2008). (Pubitemid 351611856)
66. Chewning RH, Murphy KJ. Gadolinium-based contrast media and the development of nephrogenic systemic fibrosis in patients with renal insufficiency. J. Vasc. Interv. Radiol. 18(3), 331-333 (2007). (Pubitemid 46616728)
67. Runge VM. Gadolinium and nephrogenic systemic fibrosis. AJR Am. J. Roentgenol. 192(4), W195-W196 (2009).
68. Ledneva E, Karie S, Launay-Vacher V, Janus N, Deray G. Renal safety of gadolinium-based contrast media in patients with chronic renal insufficiency. Radiology 250(3), 618-628 (2009).
69. Cowper SE. Nephrogenic systemic fibrosis: a review and exploration of the role of gadolinium. Adv. Dermatol. 23, 131-154 (2007).
70. Macfarland DK, Walker KL, Lenk RP et al. Hydrochalarones: a novel endohedral metallofullerene platform for enhancing magnetic resonance imaging contrast. J. Med. Chem. 51(13), 3681-3683 (2008). (Pubitemid 351956497)
71. Ouimet T, Lancelot E, Hyafil F et al. Molecular and cellular targets of the MRI contrast agent p947 for atherosclerosis imaging. Mol. Pharm. 9(4), 850-861 (2012).
72. Uno K, Nicholls SJ. Biomarkers of inflammation and oxidative stress in atherosclerosis. Biomark. Med. 4(3), 361-373 (2010).
73. Sadeghi MM, Glover DK, Lanza GM, Fayad ZA, Johnson LL. Imaging atherosclerosis and vulnerable plaque. J. Nucl. Med. 51(Suppl. 1), 51S-65S (2010).
74. Nergiz-Unal R, Rademakers T, Cosemans JM, Heemskerk JW. CD36 as a multiple-ligand signaling receptor in atherothrombosis. Cardiovasc. Hematol. Agents Med. Chem. 9(1), 42-55 (2011).
75. Collot-Teixeira S, Martin J, Rmott-Roe C, Poston R, Mcgregor JL. CD36 and macrophages in atherosclerosis. Cardiovasc. Res. 75(3), 468-477 (2007). (Pubitemid 47080960)
76. Ge Y, Elghetany MT. CD36: a multiligand molecule. Lab. Hematol. 11(1), 31-37 (2005). (Pubitemid 40444030)
77. Silverstein RL, Febbraio M. CD36, a scavenger receptor involved in immunity, metabolism, angiogenesis, and behavior. Sci. Signal. 2(72), re3 (2009).
78. Podrez EA, Poliakov E, Shen Z et al. Identification of a novel family of oxidized phospholipids that serve as ligands for the macrophage scavenger receptor CD36. J. Biol. Chem. 277(41), 38503-38516 (2002). (Pubitemid 35154709)
79. Kolovou G, Anagnostopoulou K, Mikhailidis DP, Cokkinos DV. Apolipoprotein E knockout models. Curr. Pharm. Des. 14(4), 338-351 (2008). (Pubitemid 351516858)
80. Patra CR, Jing Y, Xu YH et al. A core-shell nanomaterial with endogenous therapeutic and diagnostic functions. Cancer Nanotechnol. 1(1), 13-18 (2010).
81. Yigit MV, Zhu L, Ifediba MA et al. Noninvasive MRI-SERS imaging in living mice using an innately bimodal nanomaterial. ACS Nano 5(2), 1056-1066 (2011).
82. Park JH, von Maltzahn G, Ruoslahti E, Bhatia SN, Sailor MJ. Micellar hybrid nanoparticles for simultaneous magnetofluorescent imaging and drug delivery. Angew. Chem. Int. Ed. Engl. 47(38), 7284-7288 (2008).
83. Park JH, Von Maltzahn G, Zhang L et al. Magnetic iron oxide nanoworms for tumor targeting and imaging. Adv. Mater. 20(9), 1630-1635 (2008).
84. Von Maltzahn G, Ren Y, Park JH et al. In vivo tumor cell targeting with "click" nanoparticles. Bioconjug. Chem. 19(8), 1570-1578 (2008).
85. Jaffer FA, Libby P, Weissleder R. Molecular and cellular imaging of atherosclerosis: emerging applications. J. Am. Coll. Cardiol. 47(7), 1328-1338 (2006).
86. Jaffer FA, Nahrendorf M, Sosnovik D, Kelly KA, Aikawa E, Weissleder R. Cellular imaging of inflammation in atherosclerosis using magnetofluorescent nanomaterials. Mol. Imaging 5(2), 85-92 (2006). (Pubitemid 44106143)
87. Mccarthy JR, Jaffer FA, Weissleder R. A macrophage-targeted theranostic nanoparticle for biomedical applications. Small 2(8-9), 983-987 (2006). (Pubitemid 44230996)
88. Li C, Hall WA, Jin N, Todhunter DA, Panoskaltsis-Mortari A, Vallera DA. Targeting glioblastoma multiforme with an IL-13/diphtheria toxin fusion protein in vitro and in vivo in nude mice. Protein Eng. 15(5), 419-427 (2002). (Pubitemid 34601734)
89. Todhunter DA, Hall WA, Rustamzadeh E, Shu Y, Doumbia SO, Vallera DA. A bispecific immunotoxin (DTAT13) targeting human IL-13 receptor (IL-13R) and urokinase-type plasminogen activator receptor (uPAR) in a mouse xenograft model. Protein Eng. Des. Sel. 17(2), 157-164 (2004). (Pubitemid 38477742)
90. Madhankumar AB, Slagle-Webb B, Mintz A, Sheehan JM, Connor JR. Interleukin13 receptor-targeted nanovesicles are a potential therapy for glioblastoma multiforme. Mol. Cancer Ther. 5(12), 3162-3169 (2006). (Pubitemid 46092059)
91. Oberdorster E. Manufactured nanomaterials (fullerenes, C60) induce oxidative stress in the brain of juvenile largemouth bass. Environ. Health Perspect. 112(10), 1058-1062 (2004). (Pubitemid 39029159)
92. Barnaby JF. Study raises concerns about carbon particles. New York Times, 29th March (2004).
93. Zhu S, Oberdorster E, Haasch ML. Toxicity of an engineered nanoparticle (fullerene, C60) in two aquatic species, Daphnia and fathead minnow. Mar. Environ. Res. 62(Suppl.), S5-S9 (2006). (Pubitemid 43884925)
94. Henry TB, Petersen EJ, Compton RN. Aqueous fullerene aggregates (nC60) generate minimal reactive oxygen species and are of low toxicity in fish: a revision of previous reports. Curr. Opin. Biotechnol. 22(4), 533-537 (2011).
95. Chen HH, Yu C, Ueng TH et al. Acute and subacute toxicity study of water-soluble polyalkylsulfonated C60 in rats. Toxicol. Pathol. 26(1), 143-151 (1998). (Pubitemid 28100699)
96. Mori T, Takada H, Ito S, Matsubayashi K, Miwa N, Sawaguchi T. Preclinical studies on safety of fullerene upon acute oral administration and evaluation for no mutagenesis. Toxicology 225(1), 48-54 (2006).
97. Gharbi N, Pressac M, Hadchouel M, Szwarc H, Wilson SR, Moussa F. [60]fullerene is a powerful antioxidant in vivo with no acute or subacute toxicity. Nano. Lett. 5(12), 2578-2585 (2005). (Pubitemid 43088916)
98. Ibrahim M, Saleh NA, Elshemey WM, Elsayed AA. Fullerene derivative as anti-HIV protease inhibitor: molecular modeling and QSAR approaches. Mini. Rev. Med. Chem. 12(6), 447-451 (2012).
99. Luo Z, Xu X, Zhang X, Hu L. Development of calixarenes, cyclodextrins and fullerenes as new platforms for anti-HIV drug design: an overview. Mini Rev. Med. Chem. 13(8), 1160-1165 (2013).
100. Kornev AB, Peregudov AS, Martynenko VM, Balzarini J, Hoorelbeke B, Troshin PA. Synthesis and antiviral activity of highly water-soluble polycarboxylic derivatives of [70]fullerene. Chem. Commun. (Camb.) 47(29), 8298-8300 (2011).
101. Zhu ZW, Schuster DI, Tuckerman ME. Molecular dynamics study of the connection between flap closing and binding of fullerene-based inhibitors of the HIV-1 protease. Biochemistry 42(5), 1326-1333 (2003). (Pubitemid 36184074)
102. Marcorin GL, Da Ros T, Castellano S et al. Design and synthesis of novel [60]fullerene derivatives as potential HIV aspartic protease inhibitors. Org. Lett. 2(25), 3955-3958 (2000).
103. Rancan F, Rosan S, Boehm F et al. Cytotoxicity and photocytotoxicity of a dendritic C-60 mono-adduct and a malonic acid C-60 tris-adduct on Jurkat cells. J. Photoch. Photobio. B 67(3), 157-162 (2002). (Pubitemid 34965855)
104. Liu Y, Wang H. Nanomedicine: nanotechnology tackles tumours. Nat. Nanotechnol. 2(1), 20-21 (2007). (Pubitemid 46209022)
105. Saathoff JG, Inman AO, Xia XR, Riviere JE, Monteiro-Riviere NA. In vitro toxicity assessment of three hydroxylated fullerenes in human skin cells. Toxicol. In Vitro 25(8), 2105-2112 (2011).